RT Journal Article
SR Electronic
T1 Estimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.02.22270317
DO 10.1101/2022.02.02.22270317
A1 Michiels, Hege
A1 Vandebosch, An
A1 Vansteelandt, Stijn
YR 2022
UL http://medrxiv.org/content/early/2022/02/05/2022.02.02.22270317.abstract
AB An exceptional effort by the scientific community has led to the development of multiple vaccines against COVID-19. Efficacy estimates for these vaccines have been widely communicated to the general public, but are nonetheless challenging to compare because they are based on phase 3 trials that differ in study design, definition of vaccine efficacy and in the handling of cases arising shortly after vaccination. In this work, we investigate the impact of these choices on vaccine efficacy estimates, both theoretically and by re-analyzing the Janssen and Pfizer COVID-19 trial data under a uniform protocol. We moreover study the causal interpretation that can be assigned to per-protocol analyses typically performed in vaccine trials. Finally, we propose alternative estimands to measure the intrinsic vaccine efficacy in settings with delayed immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by VLAIO (Flemish Innovation and Entrepreneurship) [Baekeland grant agreement HBC.2019.2155].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available due to confidentiality restrictions. The simulated data that support the findings of this study are available on request from the corresponding author.